MMMatic Munda

Matic Munda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Matic Munda has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bridging the Gap Between Experimental and Clinical Applications of Mesenchymal Stromal Cell Therapy in Intervertebral Disc Regeneration

    by Lidija Gradisnik, Borut Prestor, Matic Munda, Tilen Zele, Uros Maver, Nina Kocivnik, Tomaz Velnar

    Intervertebral disc (IVD) degeneration is a major cause of chronic low back pain and disability worldwide. Although current treatment strategies effectively alleviate symptoms, they do not restore disc structure or reverse the underlying biological processes responsible for degeneration. Mesenchymal stromal cell (MSC)-based therapies have emerged as promising regenerative approaches owing to their immunomodulatory, anti-inflammatory, and extracellular matrix-regenerative properties, mediated predominantly through paracrine signalling rather than long-term cellular engraftment. Despite encouraging preclinical results, clinical translation remains limited by poor cell survival within the hostile disc microenvironment, protocol heterogeneity, and insufficient long-term clinical evidence. This review critically examines the current state of MSC-based therapy for IVD degeneration by integrating experimental findings, clinical evidence, and emerging translational strategies. Particular emphasis is placed on the biological mechanisms of MSC-mediated regeneration, comparison of different MSC sources, advances in extracellular vesicle- and exosome-based cell-free therapies, and the growing role of quantitative magnetic resonance imaging, molecular biomarkers, and precision diagnostics in patient selection and treatment monitoring. In addition, the review discusses the major biological, technical, manufacturing, and regulatory challenges that currently limit clinical implementation. Collectively, the evidence indicates that successful translation of MSC-based therapies will require not only optimised cell products but also standardised manufacturing, biomaterial-assisted delivery systems, advanced diagnostic biomarkers, and well-designed multicentre clinical trials. Integrating these advances will be essential for transforming MSC-based therapies into safe, standardised, and disease-modifying treatments for patients with intervertebral disc degeneration.

  • Open Access

    Atypical Skull-Base Osteomyelitis: Comprehensive Review and Multidisciplinary Management Viewpoints

    by Jure Urbančič, Domen Vozel, Saba Battelino, Roman Bošnjak, Barbara Kokošar Ulčar, Tadeja Matos, Matic Munda, Lea Papst, Nejc Steiner, Matej Vouk, et al.

    Atypical skull-base osteomyelitis is a rare but fatal disease that usually involves infection of the ethmoid, sphenoid, occipital, or temporal bones that form the skull base. Unlike typical (so-called otogenic), atypical skull-base osteomyelitis has no otogenic cause. Instead, some authors call atypical skull-base osteomyelitis sinonasal, since the infection most often originates from the nose and paranasal sinuses. Diagnosing and treating this disease is challenging. To assist in managing atypical skull-base osteomyelitis, a review of the most recent literature, with patient cases and multidisciplinary perspectives from otolaryngologists, neurosurgeons, radiologists, infectious disease specialists, pathologists, and clinical microbiologists, is provided in this paper.